H.R. 830

119th Congress

In Committee

SAFE Act

Sponsored byDemocrat:Rep. Pappas, Chris [D-NH-1]NH· Introduced 31 January 2025

17

Cosponsors

4

Actions

0

Amendments

2

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

31 January 2025·1 year ago

Summary

Introduced in House · Updated 26 September 2025

Save Americans from the Fentanyl Emergency Act or the SAFE Act

This bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Fentanyl-related substances are currently regulated under schedule I through a temporary order issued by the Drug Enforcement Administration. The temporary order expires on March 31, 2025.

It limits mandatory minimum penalties for certain offenses involving fentanyl-related substances, establishes a process to deschedule or remove certain fentanyl-related substances that have a low potential for abuse, and allows federal courts to vacate or reduce sentences for convictions involving a fentanyl-related substance that is descheduled or moved to a schedule other than schedule I or II.

The bill establishes a new, alternative registration process for schedule I research. It also makes other changes to registration requirements for conducting research with controlled substances, including

  • permitting a single registration for related research sites in certain circumstances,
  • waiving the requirement for a new inspection in certain situations, and
  • allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

Finally, the bill requires the Government Accountability Office to analyze the implementation and impact of permanently placing fentanyl-related substances into schedule I of the Controlled Substances Act.

Timeline

4 actions

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    31 January 2025 · IntroReferral

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    31 January 2025 · IntroReferral

  3. Introduced in House

    31 January 2025 · IntroReferral

  4. Introduced in House

    31 January 2025 · IntroReferral

Sponsorship

17 cosponsors

Sponsor

Democrat:Rep. Pappas, Chris [D-NH-1]NH

Cosponsors

  • Democrat1482%
  • Republican318%

Classification

Policy area

Crime and Law Enforcement

Legislative subjects

Administrative law and regulatory proceduresCongressional oversightCriminal procedure and sentencingDepartment of JusticeDrug trafficking and controlled substancesGovernment studies and investigationsInternational law and treatiesLicensing and registrationsManufacturingResearch administration and funding

Committees

2

  • Energy and Commerce Committee

    House · Standing

    • Referred To31 Jan 2025
  • Judiciary Committee

    House · Standing

    • Referred To31 Jan 2025

Cosponsor momentum

Cumulative over time

Cosponsors grew from 2 on 31 January 2025 to 17 on 17 November 2025.

Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.